Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007332 · ClinicalTrials.gov registry record · Phase 2
Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
- 17
- Study locations
NCT00007332 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 330 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (26% lower). The trial reports 17 study locations across 10 states.
The verdict
NCT00007332, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to see if the vaccines tested are safe when given alone and when given together, and how the immune system responds to the vaccines. Vaccines are given to people to try to prevent an infection or disease. Early testing in a few people has shown that the HIV vaccines ALVAC vCP1452 and AIDSVAX B/B seem to be safe to use.
Conditions Studied
Interventions
- BIOLOGICAL ALVAC(2)120(B,MN)GNP (vCP1452)
- BIOLOGICAL MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Study Locations (17)
New York
- HIV Prevention & Treatment CRS - New York
- NY Blood Ctr./Union Square CRS - New York
- Univ. of Rochester HVTN CRS - Rochester
- NY Blood Ctr./Bronx CRS - The Bronx
Maryland
- Project Brave HIV Vaccine CRS - Baltimore
- Johns Hopkins Bloomberg School of Public Health, Ctr. for Immunization Research, Project SAVE-DC - Baltimore
- Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore
California
- San Francisco Dept. of Public Health, San Francisco Gen. Hosp. - San Francisco
- San Francisco Vaccine and Prevention CRS - San Francisco
Massachusetts
- Brigham and Women's Hosp. CRS - Boston
- Fenway Community Health Clinical Research Site (FCHCRS) - Boston
Alabama
- Alabama Vaccine CRS - Birmingham
Missouri
- Saint Louis Univ. School of Medicine, HVTU - St Louis
Rhode Island
- Miriam Hospital's HVTU - Providence
Tennessee
- Vanderbilt Vaccine CRS - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007332
The ClinicalTrials.gov registry entry for NCT00007332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (26% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which ALVAC(2)120(B,MN)GNP (vCP1452) is the first listed.
NCT00007332 reports 17 study locations spanning 10 distinct geographic areas - top geographies include New York, Maryland, California.
Frequently Asked Questions
What is clinical trial NCT00007332 about?
NCT00007332 is a clinical study titled "Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B". The purpose of this study is to see if the vaccines tested are safe when given alone and when given together, and how the immune system responds to the vaccines. Vaccines are given to people to try to prevent an infection or disease. Early testing in a few people has shown that the HIV vaccines ALV...
What is the current status of trial NCT00007332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. Estimated completion is 2003-04.
What conditions does trial NCT00007332 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00007332?
The interventions under investigation include: ALVAC(2)120(B,MN)GNP (vCP1452) (BIOLOGICAL), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00007332?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007332 being conducted?
This trial has 17 study locations across Alabama, California, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.